Insights
Referenced briefings
A weekly briefing on the news that matters, from the regulators, health bodies and journals that made it. Every claim is cited.
Machine learning on baseline MRI predicts Duchenne progression to stratify trial patients
An XGBoost model forecast muscle fat-fraction trajectories with R2 of 0.94 and 0.95 and split patients into slow and fast progressors.
Read the briefingEarlier briefings
November 2026
- Flagship merges AI biotechs Valo and Montai behind a pipeline led by MTAI-1025The combined company keeps the Valo name and Brian Alexander as chief executive, with merger terms not disclosed.Markets
- Rivia launches AI trial data review module as Scancell aims to cut cleaning to two weeksScancell, the first adopter, aims to cut end-of-study data cleaning from eight weeks to two with the Swiss firm's DataFindings module.Pharma
- Boltz trains BoltzMol-1 ADMET models on Excelra's curated GOSTAR dataBoltz says it found binders or actives for six of ten hard targets while testing only 28 to 96 compounds per target.Pharma
- Pierre Fabre hires XtalPi's AI and robotics platform to design cancer drug candidatesXtalPi will design small molecules de novo for undisclosed oncology targets, with Pierre Fabre taking any candidates into the clinic.Pharma
- Recursion plans registrational trial for AI-repositioned REC-4881 after FAP data87% of 15 patients saw total polyp burden fall after 12 weeks of the Takeda-originated MEK inhibitor, with a 47% median reduction.Pharma
- NICE and NHS England pilot a shorter first appraisal to halve waits for new medicinesThe SMART pilot targets six months instead of around a year, in exchange for real-world evidence and a full NICE review later.Policy
- Insilico's generative AI-designed TEAD inhibitor shrinks mesothelioma tumours in Phase 1ISM6331 produced a 40.0% response rate at 130 mg once daily, though that figure rests on two of five evaluable patients, and no dose-limiting toxicity was seen.Pharma
- UK Sovereign AI fund co-leads eight-figure seed round for Potential SciencesCambridge-based Potential Sciences says rebuilding quantum chemistry for GPUs makes AI calculations for designing drug molecules 100 times cheaper.Markets
- MHRA sets terms for UK trials built on non-clinical data from outside the OECD systemEnhanced assessment may apply to first-in-human trials in advanced cancers, and the agency will inspect test facilities that often appear in UK applications.Policy
- UCB brings Cradle's AI protein design platform into its antibody discovery projectsThe collaboration covers selected projects from hit generation to preclinical readiness, feeding UCB's lab results back into programme-specific models.Pharma
- Nature paper describes Pinal, a 16bn-parameter model designing proteins from textPinal's designs worked in all four tasks tested, and one designed H-protein raised product titre 1.7-fold over the native E. coli version.Pharma
- AstraZeneca culls four early cancer drugs, including both prostate assets, in Q3 reviewThe cuts land as AstraZeneca reports 12 positive Phase III readouts this year and 47 approvals in major regions since its Q4 2025 results.Pharma
- Lilly's retatrutide beats Ozempic on blood sugar and doubles its weight loss in Phase 3In TRANSCEND-T2D-2, 1,298 adults with type 2 diabetes lost 19.5% to 20.9% of body weight on retatrutide against 9.4% on Ozempic 2 mg.Pharma
October 2026
- FDA grants Inovio's Voceryq first US approval for a plasmid DNA immunotherapyThe accelerated approval in recurrent respiratory papillomatosis rests on a 32-patient open-label trial and requires confirmatory studies.Policy
- Flagship merges Cellarity, Etiome and Empress into AI drug discovery company EtceleraThe combined company launches with no new funding, $374 million of prior venture backing and programmes in haematology, metabolism and immunology.Pharma
- FDA drafts route for gene therapies to add new mutations on lab data aloneUnder the draft, a first approval would set the parameters that let later variants for other mutations in the same gene skip a new clinical study.Policy
- AstraZeneca's Tagrisso plus Orpathys cuts death risk by 32% after Tagrisso resistanceGlobal Phase III SAFFRON in 338 MET-high lung cancer patients extends median survival to 17.8 months against 12.9 on chemotherapy; a US filing is in.Pharma
- FDA clears Pfizer's Talzenna combination in earlier HRR-mutated prostate cancerTALAPRO-3 in 599 patients gave a hazard ratio of 0.48 for radiographic progression-free survival, with overall survival data still immature.Pharma
- Roche's divarasib cuts risk of death by 44% against Lumakras and Krazati in Phase 3Median overall survival reached 17.7 months against 12.0 months in Krascendo 1, a 338-patient head-to-head trial in previously treated KRAS G12C lung cancer.Pharma
- Kelun and MSD's sac-TMT halves progression risk in PD-L1-negative lung cancer in Phase 3OptiTROP-Lung06 put the TROP2 antibody-drug conjugate in place of platinum chemotherapy alongside Keytruda and lifted median progression-free survival from 5.7 to 15.0 months in 455 Chinese patients.Pharma
- MHRA licenses J&J's once-daily icotrokinra pill for moderate to severe plaque psoriasisThe oral IL-23 receptor blocker was backed by four Phase 3 trials in 2,500 people, including 72 adolescents, a month after EU approval.Policy
- Amgen's Imdelltra with Imfinzi cuts risk of death by 58% in first-line small cell lung cancerMedian overall survival reached 21.1 months against 12.7 months on Imfinzi alone in the 563-patient DeLLphi-305 Phase 3 trial, presented at ESMO.Pharma
- J&J's apalutamide around prostate surgery cuts recurrence or death risk by 62% in PROTEUS substudyIn 408 high-risk patients, 63% on apalutamide plus ADT were event-free at three years against 41.4% after surgery alone; overall survival is not yet reported.Pharma
- FDA clears at-home subcutaneous induction for AbbVie's Skyrizi in Crohn's diseaseIn the 274-patient AFFIRM trial, 74% of patients new to advanced therapy reached remission at week 12, against 27% on placebo.Pharma
- Tango's vopimetostat plus Rasonque shrinks tumours in 82% of MTAP-deleted pancreatic cancersAt nine months 88% of 22 evaluable patients were alive without progression; Tango plans a front-line phase 3 trial in the first half of 2027.Pharma
- FDA accepts Biohaven's resubmission of rejected ataxia drug Vyglxia and plans a panelThe agency expects to rule on troriluzole in the first quarter of next year, after rejecting it last November over its real-world evidence design.Policy
- Merck and Moderna's mRNA cancer therapy cuts melanoma recurrence risk by 42% in Phase 3Distant metastasis-free survival improved by 38%, short of the Phase 2 result, and shares in both companies fell after leaked data forced an early release.Pharma
- FDA grants AstraZeneca's Ultomiris accelerated approval in IgA nephropathyRavulizumab cut proteinuria 43.4% versus placebo at 34 weeks in the I CAN trial, with kidney function data at week 106 needed for full approval.Pharma
- AbbVie's dual IL-1 antibody lutikizumab meets Phase 3 goal in hidradenitis suppurativaIn the 1400-patient INTREPID trial, 31.4% on lutikizumab reached HiSCR75 at Week 16 against 23.4% on placebo; filings are planned for the second half of 2027.Pharma
- Roivant's brepocitinib beats placebo in two Phase 3 uveitis trials and heads for a US filingMedian time to treatment failure passed 48 weeks on Priovant's JAK inhibitor against 12 weeks on placebo in Clarity-1 and Clarity-2.Pharma
- MHRA licenses Arrowhead's quarterly plozasiran for familial chylomicronaemia syndromeThe approval came via the International Recognition Procedure, backed by a 75-patient study showing a median triglyceride fall of around 80% versus 17% on placebo.Pharma
- MHRA withdraws UK licence for IXCHIQ chikungunya vaccine after safety reviewSerious reactions including encephalitis, some fatal, led the Commission on Human Medicines to judge the vaccine's risks now outweigh its benefits.Policy
- Insilico hits first milestone in $888m AI oncology discovery deal with ServierBoth programmes have nominated targets within 10 months, as Insilico reports 11 preclinical candidates so far in 2026 and its first profitable half-year.Pharma
- FDA approves GSK's Hibsago as first antisense drug for chronic hepatitis BIn two Phase III trials 19% of treated patients kept the virus controlled 24 weeks after stopping all therapy, against none on placebo.Pharma
- Amgen and AstraZeneca's Tezspire holds EoE remission to one year in Phase 3 CROSSINGHistologic remission reached 67.8% on the 210 mg dose at week 52 against 5.4% on placebo in the 368-patient trial.Pharma
- Disc Medicine's bitopertin meets all Phase 3 goals in EPP after FDA rejection in FebruaryThe oral GlyT1 blocker cut PPIX by about 46% against just over 4% on placebo, and Disc plans to refile with the FDA by the end of the year.Pharma
- FDA grants GSK's Jemperli accelerated approval in dMMR locally advanced rectal cancerThe decision on 19 October rests on interim phase 2 AZUR-1 data in 154 patients and came nearly 4 months ahead of schedule under a priority voucher.Pharma
- J&J's Tremfya lifts Crohn's fistula remission to 35% at one year in Phase 3 FUZIONCombined clinical and MRI remission on the 100 mg dose rose from 28% at week 24, and more than 90% of patients stayed on treatment through week 48.Pharma
- Nouscom raises €120m to take Lynch syndrome cancer vaccine into a registration trialEvery evaluable carrier given NOUS-209 in phase 1b/2 stayed free of advanced adenomas and colorectal cancer, with two-year data on 17 people.Markets
- EMA confirms refusal of Omeros' narsoplimab after re-examination in transplant TMAThe agency said a 28-patient uncontrolled study could not show Yartemlea's benefit, and ruled out a conditional authorisation as a fallback.Policy
- Danaher and NVIDIA move to build AI models into lab instruments for drug discoveryThe collaboration starts with a few priority instruments and sits alongside a Danaher autonomous lab that NVIDIA says targets up to 8x faster reagent discovery.Pharma
- MHRA licenses catumaxomab to lengthen the gap between drainages for malignant ascitesIn a 258-patient study, patients went around 46 days before needing further drainage, against 11 days with drainage alone.Pharma
- China drafts ban on foreign takeovers of its cell and gene therapy and siRNA platformsLicensing and contract research stay open under the Commerce Ministry draft, which is out for comment until 15 November.Policy
- Cerevance's non-dopamine Parkinson's pill solengepras meets Phase 3 goal on off timeThe 150 mg dose cut daily off time by 0.61 hours against placebo at 12 weeks in 341 patients already taking levodopa.Pharma
- Dutch court bars MSD's subcutaneous Keytruda from eight European marketsThe Hague ruling upholds Halozyme's MDASE patent EP622 and follows a German injunction from December 2025; intravenous Keytruda is unaffected.Pharma
- FDA launches rare disease framework to tailor evidence and manufacturing reviewsA public meeting on 28 October opens consultation; the agency says only about 5% of rare conditions have an FDA-approved treatment.Policy
- Arrowhead's under-the-skin RNAi drug cuts brain protein tau by 73% in early trialARO-MAPT is the first subcutaneous RNAi medicine shown to cross into the brain, and the data point to dosing once every three months.Pharma
- EMA committee backs Lilly's oral GLP-1 Foundayo for EU obesity and diabetes useApproval would make it the EU's second oral GLP-1 after Novo's Wegovy pill, which sold about $850 million in the first half against Foundayo's $98 million.Policy
- MHRA adds boxed warning and patient card to leaflets for antidepressantsLeaflets for 10 antidepressants will name post-SSRI sexual dysfunction, and a separate benefits and risks leaflet follows in 2027.Policy
- Osivax's nucleoprotein flu vaccine misses Phase 2b goal with 24% efficacy and pivots to combinationsThe 2,850-person European trial needed 50% efficacy; the French biotech will now pair OVX836 with seasonal shots, starting with GC Biopharma's GC FLU.Pharma
- EMA backs Revolution Medicines' Rasonque for pancreatic cancer after a sub-150-day reviewIn a 500-patient phase 3 study, median survival was 12.4 months on the oral RAS inhibitor against 6.7 months on chemotherapy.Pharma
- BioNTech's mRNA immunotherapy BNT113 misses progression goal in Phase 3 head and neck trialThe AHEAD-MERIT study continues to an overall survival readout that could still make it positive, but BioNTech shares fell on the news.Pharma
- FDA extends ImmunityBio's Anktiva to papillary-only bladder cancer without a new trialThe agency extrapolated efficacy from a 77-patient carcinoma in situ cohort and plans to set the approach out in final guidance for other developers.Pharma
- MHRA licenses Lilly's once-weekly insulin Onswik, meeting NICE's condition for NHS useThe 13 October authorisation for adults with type 2 diabetes meets the licensing condition NICE attached to its August final draft guidance.Pharma
- MHRA 2030 strategy halves Phase 1 trial review target and plans AI protocol checkerThe UK regulator will offer paid fast-track scientific advice in 45 days rather than 90 and publish an AI medicines development action plan in 2027.Policy
- AbbVie's under-the-skin Skyrizi induction lifts Crohn's endoscopic remission to 35.8%Phase 3 AFFIRM data at week 24 back filings with the FDA and EMA, but rates fall to 30.1% in patients who had already failed advanced therapyPharma
- Roche licenses Rona's ALK7 RNAi obesity candidate for up to $100m near termRona is also eligible for up to $1.06 billion in milestones plus royalties as Roche joins Alnylam, Arrowhead, GSK and Novo in chasing the fat-tissue target.Markets
- ViiV's injectable Cabenuva beats daily pills in people with detectable HIV in Phase 3b CROWNThe 326-person trial tested starting injections without first suppressing the virus on tablets, a use regulators have not approved; data will go to health authorities.Pharma
- Bristol Myers' admilparant meets Phase 3 IPF goal at 60 mg but misses at 120 mgAnalysts question the absent dose response as Bristol Myers prepares filings for what could be the first LPA1 antagonist approved for IPF.Pharma
- Forbion closes €2.3bn across two funds, the largest raise in its historyLilly, Dutch pension managers MN and PGGM and KfW Capital back the Dutch investor, which can now fund up to 30 young life sciences companies.Markets
- FDA clears Roche's Tecentriq after surgery for stage III dMMR colon cancerIn the phase III ATOMIC trial, adding Tecentriq to chemotherapy halved the risk of recurrence or death, with 86% disease-free at three years against 76%.Pharma
- Vaxcyte's 31-strain pneumococcal vaccine matches Pfizer and Merck shots in Phase 3VAX-31 was non-inferior on all 20 Prevnar 20 strains and 17 of 19 Capvaxive strains in 3,500 adults, sending shares up 57%.Pharma
- CSL pays Alentis $355 million upfront to co-develop claudin-1 antibody lixudebartAlentis can earn up to $1.2 billion more in commercial milestones, and CSL will fund the trials in exchange for 55% of global profits.Markets
- Lilly-backed TRex Bio raises $116.7 million in Nasdaq IPO priced at $14 a shareLilly held about 24% of the Treg drug developer before the listing; first Phase 1 data for lead drug TRB-061 are due in mid-2027.Markets
- Shionogi agrees to buy IntraBio for $2 billion to add rare disease drug AqneursaAqneursa, approved for Niemann-Pick disease type C and ataxia-telangiectasia, brought IntraBio $68 million in sales in 2025.Markets
- Argenx halts Phase 3 Vyvgart study in Sjögren's disease after futility findingShares in the Dutch biotech fell 15% on 8 October, removing an indication some analysts valued at up to $1.4 billion in peak sales.Pharma
- GSK signs up for Chai Discovery's AI protein design models after its own wet-lab testsGSK found binders to every target it tested, joining Bristol Myers Squibb, Lilly, Novartis and Pfizer as users of Chai's platform.Pharma
- Viatris agrees to buy Pacira BioSciences for $1.65 billion to build its pain portfolioViatris will pay $36.50 a share in cash, a 45% premium, for two non-opioid pain drugs that booked $692 million in 2025.Markets
- Sanofi pays Regeneron $1 billion upfront for four next-generation Dupixent successorsRegeneron can earn up to $7 billion in milestones as the partners split costs and profits on long-acting IL-4 and IL-13 antibodies.Markets
- Biohub, DOE and NIH commit $1.8 billion to open data for AI models of cellsGoogle DeepMind, Isomorphic Labs and Meta are putting $300 million into the Virtual Biology Initiative, which aims to build an open, AI-ready biology dataset.Pharma
- PhRMA sues to block Medicare's GLOBE pilot tying Part B rebates to 19 countries' pricesThe final rule covers only four companies and CMS now expects $440 million in savings, but the industry fears a template for Part D.Policy
- Novartis pays Abogen $575 million upfront for mRNA-encoded T-cell engager ABO2203Abogen, based in Suzhou, could receive up to approximately $7.2 billion more in milestones if Novartis exercises all options on its RNA programmes.Markets
- Genmab and AbbVie's epcoritamab cuts lymphoma progression risk by 51% in frontline Phase 3The EPCORE DLBCL-2 result in newly diagnosed DLBCL beat investor expectations of about 40%, and the partners will now engage regulators.Pharma
- Nature Biotechnology analysis finds deep learning perturbation models can beat baselinesAcross 14 datasets and 18 metrics, common measures such as mean squared error and Pearson Δ were frequently miscalibrated, the authors report.Pharma
- AI chatbot beats government leaflet on HPV vaccine literacy but not on uptake decisionsIn an 848-caregiver randomised trial in Japan, 40.3% in the chatbot arm and 39.6% in the leaflet arm decided to vaccinate at 2 weeks.Pharma
- Enveda raises $311 million series E to push AI-found drugs into later trialsThe Catalio-led round funds phase 2 work on eczema pill ENV-294, which cut eczema severity by a mean 68% by Day 28 in a phase 1b study.Pharma
- Government accepts all 44 AI Commission recommendations as MHRA opens AI Airlock Phase 3The MHRA will issue draft guidance on changes to AI-enabled devices by December 2026, with a full implementation roadmap due by Spring 2027.Pharma
- AI framework AGENT yields mRNA vaccines stable at 37 °C for two monthsSolid-state mRNA–lipid nanoparticle formulations gave immune responses non-inferior to fresh vaccines in rodents and nonhuman primates, Nature Biotechnology reports.Pharma